Related Experiment Video
Updated: May 12, 2026
Experimental Metastasis and CTL Adoptive Transfer Immunotherapy Mouse Model
Published on: November 26, 2010
Systemic IFN-beta gene therapy results in long-term survival in mice with established colorectal liver metastases
1Department of Surgery, Division of Surgical Oncology, University of Pennsylvania Medical Center, Philadelphia, Pennsylvania 19104, USA.
Abstract:
Most patients succumbing to colorectal cancer fail with liver-predominant metastases. To make a clinical impact in this disease, a systemic or whole-liver therapy may be required, whereas most cancer gene therapy approaches are limited in their ability to treat beyond local disease. As a preclinical model for cancer gene therapy, recombinant adenovirus containing the human IFN-beta (hIFN-beta) cDNA was delivered systemically in nude mouse xenograft models of human colorectal cancer liver metastases. The vector targeted hepatocytes that produced high levels of hIFN-beta in the liver, resulting in a profound apoptotic response in the tumors and significant tumor regression. hIFN-beta gene therapy not only resulted in improved survival and long-term cure in a micrometastatic model, but provided similar benefits in a clinically relevant gross disease model. A similar recombinant adenovirus containing the murine IFN-beta (mIFN-beta) cDNA also resulted in a therapeutic response and improved survival in syngeneic mouse models of colorectal cancer liver metastases. Depletion studies demonstrate a contribution of natural killer cells to this therapeutic response. The toxicity of an adenoviral vector expressing murine IFN-beta in a syngeneic model is also presented. These encouraging results warrant further investigation of the use of cancer gene therapy for targeting metastatic disease.
Insights
Systemic gene therapy using adenovirus delivering interferon-beta effectively treated colorectal cancer liver metastases in preclinical models. This approach demonstrated significant tumor regression, improved survival, and long-term cures, warranting further investigation for metastatic disease.
Area of Science:
- Oncology
- Gene Therapy
- Hepatology
Background:
- Colorectal cancer frequently metastasizes to the liver, posing a significant clinical challenge.
- Current gene therapy approaches often struggle to treat widespread metastatic disease effectively.
- Systemic or whole-liver therapies are needed to impact liver-predominant colorectal cancer.
Purpose of the Study:
- To evaluate the efficacy of systemic adenoviral-mediated interferon-beta gene therapy in preclinical models of colorectal cancer liver metastases.
- To assess the therapeutic potential of both human (hIFN-beta) and murine (mIFN-beta) interferon-beta gene therapy.
- To investigate the contribution of natural killer cells and the toxicity profile of the adenoviral vector.
Main Methods:
- Systemic delivery of recombinant adenovirus carrying hIFN-beta cDNA in nude mouse xenograft models.
- Treatment of syngeneic mouse models with adenovirus carrying mIFN-beta cDNA.
- Assessment of tumor response, survival rates, and natural killer cell contribution.
- Evaluation of adenoviral vector toxicity.
Main Results:
- Systemic hIFN-beta gene therapy led to significant tumor regression and apoptosis in liver metastases.
- Improved survival and long-term cures were observed in both micrometastatic and gross disease models.
- mIFN-beta gene therapy also showed therapeutic benefits and improved survival in syngeneic models.
- Natural killer cells were found to contribute to the therapeutic response.
Conclusions:
- Adenoviral-mediated interferon-beta gene therapy is a promising strategy for treating colorectal cancer liver metastases.
- The systemic delivery approach shows potential for clinical impact in managing metastatic disease.
- Further research is warranted to explore this gene therapy for advanced colorectal cancer.
